Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2025-03-17 Audit Report / Informat…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for HLB Therapeutics, covering the fiscal year 2024. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and notes to the financial statements. It is a comprehensive financial document, not an announcement or a summary, and therefore fits the 'Audit Report' category. FY 2024
2025-03-17 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Therapeutics. It contains the meeting agenda, voting procedures, director activity reports, and business overviews. In the context of financial filings, this document is a formal proxy statement and notice sent to shareholders to solicit votes and provide information for the upcoming Annual General Meeting. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2025-03-05 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding a significant change in financial structure (revenue/profit/loss) exceeding 30%. This is a standard disclosure requirement in the Korean market (DART system) for preliminary financial results before the final audit report is finalized. Since it provides key financial highlights and management's explanation for the variance, it fits the 'Earnings Release' (ER) category as it serves as the initial announcement of financial performance for the period. FY 2024
2025-03-05 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights). It contains information regarding the upcoming Annual General Meeting (AGM), including the meeting date, agenda items (such as approval of financial statements), and instructions for shareholders to exercise their voting rights via proxy, electronic voting, or written ballots. This document is a standard proxy solicitation material provided to shareholders to request their votes for the meeting.
2025-03-05 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by HLB Therapeutics. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting, including financial statement approval, articles of incorporation changes, and director/auditor remuneration. This document serves as the official notification to shareholders regarding the meeting logistics and agenda, which falls under the Proxy Solicitation & Information Statement category as it provides the necessary information for shareholders to exercise their voting rights.
2025-03-05 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and logistics of an upcoming Investor Relations (IR) event (a shareholder meeting/presentation). It specifies the date, time, location, and purpose of the event. Since it is an announcement of an event rather than the presentation materials themselves, and it is a short regulatory notice, it falls under the category of a Report Publication Announcement or general regulatory filing regarding corporate events.
2025-03-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.